Related Experiment Videos
Dexmedetomidine failed to block the acute hyperdynamic response to electroconvulsive therapy
1Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center at Dallas, 75235-9068, USA.
Anesthesiology
|February 10, 1999
Summary
Dexmedetomidine did not effectively manage the hypertensive response to electroconvulsive therapy (ECT). This investigational drug, given intravenously, also prolonged patient recovery times post-ECT.
Area of Science:
- Anesthesiology
- Pharmacology
- Critical Care Medicine
Background:
- Clonidine has shown efficacy in mitigating acute hypertensive responses during electroconvulsive therapy (ECT).
- Investigational alpha2-adrenergic agonist dexmedetomidine's hemodynamic effects in ECT patients require evaluation.
Purpose of the Study:
- To assess the acute hemodynamic effects of intravenous dexmedetomidine in patients undergoing ECT.
- To determine if dexmedetomidine can control the hyperdynamic response to ECT.
Main Methods:
- A randomized, double-blind, placebo-controlled study involving six patients undergoing ECT.
- Patients received intravenous saline or dexmedetomidine (0.5 or 1.0 microg/kg) pre-ECT.
- Evaluated cardiovascular variables, seizure duration, sedation, and recovery times.
Main Results:
- Dexmedetomidine increased sedation pre-ECT in a dose-dependent manner.
- It failed to reduce peak blood pressure and heart rate responses post-ECT.
- Both dexmedetomidine doses prolonged orientation and discharge times from recovery.
Conclusions:
- Intravenous dexmedetomidine (0.5-1.0 microg/kg) is not beneficial for controlling the acute hyperdynamic response following ECT.
- The drug prolonged recovery times, indicating potential adverse effects.